Summary of South Korea’s Bio-Pharma Industry in 2025
This article highlights a year of significant growth and change for South Korea’s biopharmaceutical industry, marked by strong performance, technological advancements, and emerging challenges. Here’s a breakdown of the key takeaways:
1. AI-Driven Drug Advancement is a National Priority:
* Government Investment: Both the government and industry are heavily investing in AI for new drug development, with projects totaling 37.1 billion won.
* Industry Adoption: Companies like Samsung BioLogics, GC Green Cross, Samjin Pharmaceutical, and Daewoong Pharmaceutical are actively integrating AI into their R&D processes – from preclinical data analysis to clinical trial prediction.
* Potential Impact: AI is projected to drastically reduce drug development time (from 15 to 7 years) and cost (from 3 trillion to 600 billion won).
2. Record performance by Industry Leaders:
* Samsung BioLogics: Achieved record Q3 sales (KRW 1.6602 trillion) and cumulative orders (KRW 5.5193 trillion) due to full factory capacity. Expanded production capacity with a 5th factory and a US acquisition.
* Celltrion: Reported its highest quarterly performance (sales of 1.029 trillion won, operating profit of 301.4 billion won) driven by biosimilar sales. Strengthened North American production through acquisition of Eli Lilly facilities.
3.Booming Technology Exports:
* All-Time High: Technology exports reached a record $14.53 billion (roughly 20 trillion won), a 162% increase year-over-year.
* Key Deals: Significant deals included:
* Alteogen: Option contracts for its Hybrozyme technology.
* RigaChem Bio: Multiple antibody introduction contracts, following previous exports to Johnson & Johnson and Ono Pharmaceuticals.
* ABL Bio: Technology transfer agreement with Lilly valued at 3.8 trillion won.
4. Emerging Challenges & Strategic Responses:
* US Trade Policy Uncertainty: Potential tariffs on imported drugs proposed by former President Trump pose a significant risk.
* Proactive Mitigation: Samsung BioLogics and Celltrion are responding by increasing local production in the US and diversifying supply chains.
* Drug Pricing System Review: Discussions are underway for a comprehensive reform of the drug pricing system.
the article paints a picture of a thriving South Korean biopharmaceutical industry poised for continued growth,but also facing potential headwinds that require strategic adaptation.
